These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18316434)

  • 1. Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
    Hazra M; Mamo DC; Remington G
    Am J Psychiatry; 2008 Mar; 165(3):396-7; author reply 397-8. PubMed ID: 18316434
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
    Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
    J Clin Psychopharmacol; 2011 Jun; 31(3):400-1; author reply 401. PubMed ID: 21532377
    [No Abstract]   [Full Text] [Related]  

  • 3. Some adverse effects of antipsychotics: prevention and treatment.
    Lader M
    J Clin Psychiatry; 1999; 60 Suppl 12():18-21. PubMed ID: 10372605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of symptomatic hyperprolactinemia by aripiprazole.
    Wahl R; Ostroff R
    Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
    [No Abstract]   [Full Text] [Related]  

  • 5. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.
    Kuo J; Hwu HG
    Clin Neuropharmacol; 2008; 31(3):173-5. PubMed ID: 18520984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
    Nunes LV; Moreira HC; Razzouk D; Nunes SO; Mari Jde J
    J Sex Marital Ther; 2012; 38(3):281-301. PubMed ID: 22533871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
    J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
    Lorenz RA; Weinstein B
    J Clin Psychopharmacol; 2007 Oct; 27(5):524-5. PubMed ID: 17873694
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1157-8; author reply 1159. PubMed ID: 20381569
    [No Abstract]   [Full Text] [Related]  

  • 10. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole and extrapyramidal symptoms.
    Lindsey RL; Kaplan D; Koliatsos V; Walters JK; Sandson NB
    J Am Acad Child Adolesc Psychiatry; 2003 Nov; 42(11):1268-9. PubMed ID: 14566162
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of Aripiprazole and extra pyramidal side effects.
    Salmoiraghi A; Odiyoor M
    J Psychopharmacol; 2006 Jul; 20(4):592-3. PubMed ID: 16401661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
    Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1361-2. PubMed ID: 20647025
    [No Abstract]   [Full Text] [Related]  

  • 14. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 15. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist.
    Burke MJ; Lincoln J
    Ann Clin Psychiatry; 2006; 18(2):129-30. PubMed ID: 16754419
    [No Abstract]   [Full Text] [Related]  

  • 17. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.
    Correll CU
    J Clin Psychiatry; 2011 Jan; 72(1):e01. PubMed ID: 21272508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Strous RD; Lerner V
    Am J Psychiatry; 2005 Mar; 162(3):631-2; author reply 632-3. PubMed ID: 15741496
    [No Abstract]   [Full Text] [Related]  

  • 19. Antipsychotic drugs--an update.
    Charalampous KD; Keepers GA
    J Okla State Med Assoc; 1978 Jan; 71(1):6-9. PubMed ID: 23420
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole.
    Huang WL; Chang LR
    Psychiatry Clin Neurosci; 2012 Apr; 66(3):245. PubMed ID: 22443252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.